There has as yet been no descriptive study of the practice of radical prostatectomy in the general population in France. The objective of this work was to investigate the use of radical prostatectomy (RP) in France and its determinants and geographic variations. A total of 175 radical prostatectomies was identi®ed in a random sample of 798 cases of prostate cancer recorded in 1995 by four cancer registries, in the departments of Bas-Rhin, Calvados, Ise Áre and Tarn. Tumour characteristics, diagnostic procedures and histopathological results were analysed. Multivariate analysis by logistic regression was used to take into account age, prostate speci®c antigen (PSA) levels and clinical stage in order to study variations between geographical departments and sectors of activity (private or public). The mean age of the patients at the time of diagnosis was 65.3 y (range 46 ± 76). Median PSA level was 18.2 ng/ml (range 1 ± 184). Diagnosis was made by randomised biopsies in 73.8% of cases or by transurethral resection (6.9%). Clinical stage was classi®ed T 1 (22.3%), T 2 (64%), T 3 (8.6%), N (0.6%) and unknown (4.5%). The histopathological result was pT 2 N0 in 46.3% of cases, pT 3 N0 in 40%, pT 4 N0 in 1.7%, pT x N in 8.6% and unknown in 3.4%. Adjuvant therapy (radiotherapy 13.7%, hormonal treatment 13.7% or both 3%) was administered in 54 patients (31%). Logistic regression showed that the probability of undergoing RP was three times higher in one department than in the other departments, and was 2.6 times as high in the private sector. This study on the practice of RP is the ®rst performed in the general population in France. It shows that practice differs according to geographical region and sector of activity, indicating that schools of thought and medical culture vary within the same country. Prostate Cancer and Prostatic Diseases (2001) 4, 118±123.
Introduction
The detection of early prostate cancer increased markedly in the 1980s, resulting in a pronounced increase in radical prostatectomy (RP) in the USA. 1 In the general population in France, determinants of treatment choices in prostate cancer are unknown. This is also true of RP, whose frequency has markedly increased over the last 10 y because routine Prostate speci®c antigen (PSA) measurement has led to increased frequency of diagnosis of localised carcinomas and also because of improved surgical technique and decrease in postoperative sequels. 2 Radical prostatectomy is regularly proposed as curative treatment to patients with localised prostatic adenocarcinoma, although it is advocated only if the patient has an estimated life expectancy of more than 10 y. 3, 4 On the initiative of the Comite Â de Cance Ârologie de l'Association FrancËaise d'Urologie (CCAFU) and the French network of Cancer Registries, a populationbased study was carried out to obtain information on practices regarding management of prostate cancer during the year 1995 in four French cancer registries. One of the aims of this investigation was to provide clinicians and epidemiologists with a recent, unbiased evaluation of the practice of RP in France and to reveal any disparities between regions and sectors of activity.
Patients and methods
Data were obtained from a random sample of 798 cases of prostate cancer recorded in 1995 by cancer registries in four French geographic departments: Bas-Rhin, Calvados, Ise Áre and Tarn. These four departments differed by their geographical situation and by availability of health care facilities. They are situated in distant regions of France (NE, NW and SW) and represented 3 million inhabitants (about 6% of the French population) with disparities in urbanisation (Tarn and Calvados were more rural) and health care distribution (no university hospital in Tarn, Comprehensive Cancer Centres only in Calvados and Bas-Rhin). There was some discrepancy in urologist distribution, especially in the SW of France where the urologists of the private sector were more numerous than in NE and NW.
This study applied to patients treated by RP. Of the 180 patients who received RP, only 175 patients operated on no later than one year after diagnosis were analysed. They represented 21.9% of the initial population of 798 patients with prostate cancer. Of this total population, 73% were managed in the private sector and 27% in the public sector.
Characteristics of patients and of tumours, diagnosis procedures, management and treatment according to sector of activity were collected from medical records by investigators from each registry, using a questionnaire prepared by the CCAFU. Various clinical indicators were noted: urinary symptoms, ®ndings of digital rectal examination (DRE), pre-operative PSA levels, diagnostic procedure (biopsies or transurethral resection), pathological results of the samples. The clinical stage of the tumours was reassessed by centralised analysis of all questionnaires according to the Tumour-Node-Metastasis classi®cation in use at this period (TNM 1992) .
To identify determinants of the practice of RP, we used bivariate analysis (w 2 test) to study the frequency of RP according to selected factors. We used a logistic regression in multivariate analysis to take into account the associations between the various factors. Wald test was performed in order to test each variable modality. Results were expressed as an adjusted odds ratio (aOR) comparing the modalities of a variable with a reference modality. All analysis was done using Stata software. 5 
Results

Age groups
The mean age at diagnosis of the 175 patients who had had RP was 65.3 y (range 46 ± 76 y), whereas the mean age of the total population of 798 patients was 71.6 y (46 ± 94). Of these 175 patients, 77.1% were aged less than 70 y and 20% were aged between 70 and 75 y. No patient had surgical treatment after the age of 76 y ( Table 1) .
Circumstances of diagnosis
At diagnosis 63% of patients presented symptoms, usually urinary (95% of cases). There was no difference between the age groups. Diagnosis was made on elevated PSA levels alone in 32% of cases (P 0.001).
Prostate speci®c antigen
Prostate speci®c antigen had been measured before diagnosis in 96.6% of cases. In 44.6% of patients PSA levels were already under surveillance before diagnosis. Median PSA was 18.2 ng/ml (range 1 ± 184 ng/ml) with a normal level of less than 4 ng/ml for the population as a whole. PSA was less than 10 ng/ml in 35.4% of patients, less than 4 ng/ml in 5.7% and above 50 ng/ml in 4.6%. In 3.4% of patients PSA measurement had been done but the results were unknown (Table 2) .
Clinical staging
Clinical stage was de®ned from the various clinical ®nd-ings and the evaluation of extent of disease. DRE had been performed in all cases but the ®ndings were unknown in 3.4% The tumour was classi®ed as T 1 in 22.3% of cases, T 2 in 64% and T 3 in 8.6% (Table 3) . Of the 39 stage T 1 tumours, 27 were T 1c , 8 T 1b and 4 T 1a . Clinical stages did not differ signi®cantly between the private and public sectors (P 0.74). 
Diagnostic procedures for prostate cancer
Prostate biopsy (PB) was performed in 159 patients (90.9%), mainly in those aged less than 70 y (97%). The technique used was not always speci®ed but 78.3% of patients had had at least randomised needle biopsies with transrectal ultrasonography. Tumoral diagnosis was established by transurethral resection of the prostate (TURP) in only 12 patients (6.9%), in particular when PSA was lower than 4 ng/ml (10 cases). The two techniques, TURP and PB, were used simultaneously in four patients (2.3%) and the result was positive in all.
Histopathologic data of diagnosis
Practice of randomised PB did not differ according to patient age group, PSA level or sector of activity of the urologist, whether private or public. The mean Gleason score of the biopsies was 5.8 (3 ± 10). In the 6.9% of diagnoses made by TURP, the mean Gleason score was 5 (3 ± 9).
Evaluation of the extent of disease
The two most frequent investigations to evaluate the extent of disease were bone scan and pelvic computerised tomography (CT scan). A bone scan had been performed in 84% of patients and in 75% of these cases PSA was above 10 ng/ml. The bone scan was normal in all cases. Pelvic CT scan had been done in 77% of patients, of whom 70% were aged less than 70 y. In 90% of these cases, no pelvic adenopathy or other abnormality was found.
Radical prostatectomy
We included in our study all patients who had had RP, whether alone or in association with adjuvant therapy (radiotherapy and/or hormonal therapy) operated on no later than one year after diagnosis. In half of these 175 cases, surgery was performed within 50 days of diagnosis.
Histological staging
Pelvic lymphadenectomy was carried out in 97.7% of cases. Sample analysis showed 46.3% stage pT 2 N 0 M 0 , 40% pT 3 N 0 M 0 , 1.7% pT 4 N 0 M 0 and 8.6% pT X N ( Table  3 ). The Gleason score of the operative samples was 7 in 43.4% of samples (with 5% unknown). Of pT 2 tumours, 71% had a Gleason score`7. Of pT 3 , pT 4 and pN tumours, 60% had a Gleason score 7. Radical prostatectomy was the only treatment in 122 cases (69.8%) and was followed by an adjuvant treatment in 53 (31%): 24 with radiotherapy (13.7%), 24 with hormonal treatment (13.7%) and six with radiotherapy plus hormonal treatment (3.4%). Age group or PSA level did not signi®cantly in¯uence administration of postoperative adjuvant therapy, unlike histopathological stage (P 0.009). Differences also existed between geographical departments (50% of patients in the Calvados had adjuvant therapy, P 0.02), but not between sectors of activity (Table 4) .
Factors in¯uencing application of radical prostatectomy
Radical prostatectomy was the main treatment modality in 21.9% of the total population of 798 patients with prostate cancer. The other treatments carried out in these 798 patients were radiotherapy (19.4%), hormonal treatment (33.1%), TURP only (17.7%) and expectative management (6.1%) (article submitted).
Multivariate analysis by estimation of the adjusted odds ratio (aOR) aimed to determine the probability of having RP after adjustment for the other medical determinants: age, PSA level, clinical stage of the tumour, and non-medical determinants: geographical department and sector of activity (Table 5) . Radical prostatectomy decreased regularly with patient age, especially after the age of 70, and patients over 76 y were not treated surgically. Its frequency was maximal for PSA levels between 4 and 20 ng/ml (P not signi®cant). Clinical stage T 2 was the best represented (aOR: 3.4, P`0.0001). Radical prostatectomy represented 40% of treatments for stages T 2 N 0 M 0 in the total population of 798 patients.
Variations between departments and sectors of activity
The practice of RP varied according to department. Frequency was higher in the Tarn (36% of treatments for prostate cancer) whereas in the other three departments the percentage ranged between 16 and 19%. Seventythree per cent of the total population of 798 patients with prostate cancer were treated in the private sector. Eighty-seven per cent of patients receiving RP (152 of the showed that RP was at least 3.5 times more frequent for patients living in the Tarn department than in the other departments (P`0.0001) and was 2.6 times higher for patients followed in the private sector (P 0.005). To determine whether the high proportion of RP in the Tarn was due only to the strong representation of the private sector in this department, separate analyses were carried out for each sector. The differences between departments persisted. Study of variations in indications of RP between the four departments showed that, in the Tarn, the difference did not concern stage T 1 but rather stage T 2 and by extension stage T 3 tumours, and this held true when use of RP was classi®ed according to PSA level. Study of variations in RP between the private and public sectors according to these medical criteria showed that RP was more frequent in the private sector (Figures 1  and 2 ).
Discussion
This study on practice of RP in general population is the ®rst performed in Europe and particularly in France. Previous French population studies have addressed the question of cancer management, colorectal cancer in particular, but this is the ®rst to deal with prostate cancer. 6, 7 To date, selection of RP in the general population was unknown in different regions of a same country. In France, RP is not centralised in specialised cancer treatment centres but is performed either in public hospitals or private clinics. Practice of RP has been evaluated in the United States and has shown geographic and temporal variations and also differing practices according to the region studied. 8, 9 The geographic variation in the selection of RP was interpreted as regional differences in physician and demographic management of prostate cancer. 1, 8 Between 1984 and 1990, a 6-fold increase in Indications were extended to men over 75 y of age. 10 During the same interval, Mettlin showed only a 2-fold increase in RP from centres participating in the National Cancer Data Base. 11 In contrast, the increased application of RP in the south of The Netherlands was restricted to men under 70 y of age. 12 No reports from other European countries are available for comparison. The large increased application of RP results from the exponential increase in the incidence of localised prostate cancer since 1990 in countries like the USA, The Netherlands and two regions of France. 2, 10, 12, 13 While hospital series are worthwhile for evaluation of diagnostic and technical innovations, they call on selected groups of patients who are not representative of the dissemination of practices in the population, notably regarding selection of RP. This study, directed by CCAFU and the Francim network, made use of the data of four French cancer registries in regions which have suf®cient sociological, demographic and geographic differences to be representative of the situation regarding prostate cancer in 1995 (article submitted). RP was part of the treatment of 21.9% of the initial population of 798 patients with prostate cancer. It involved a group of relatively young patients whose mean age was 65.3 y and who were not older than 76 y, which is similar to practice habits in Europe and in the USA. 2, 11, 12 In a recent report of the use of RP in nine geographic regions of USA, only age appeared to meaningfully explain the variation in RP of the different factors examined. 8 In our study, RP mainly concerned organ-con®ned tumours (86.3%), in particular stage T 2 tumours which were three times more frequent than the other stages. The proportion of stage T 1c in our series represented only 15.4% (27 patients). These results are markedly lower than those of the series of Stamey, in which stage T 1c increased from 10% in 1988 to more than 70% in 1996. 14 This difference in clinical stage at the time of diagnosis is due to the absence of mass screening in France, whereas screening is done in some states in North America and accounts for the greater number of stage T 1c tumours. Most PSA levels were between 4 and 20 ng/ml, and median PSA was 18.2 ng/ml. Preoperative evaluation of the extent of disease showed that CT scan provided no useful information concerning operative indication and that bone scintigraphy was nearly always normal with organ-con®ned tumours, even if PSA levels were higher than 20 ng/ml.
The histopathological results showed clinical understaging of about 40% with regard to pathological staging of RP specimens and Gleason score of the biopsy cores. Only 46.1% of operated tumours were organ-con®ned on the specimen (pT 2 ) whereas 86.3% of tumours were preoperatively classi®ed T 1 or T 2 and 8.6% had lymph node involvement. The status of the surgical margins on the specimen could not be assessed because of lack of uniformity of the histopathological reports. However, 31% of RP were completed by adjuvant therapy, either radiotherapy or hormonal treatment, in the year following diagnosis. For prescription of adjuvant therapy, no determinant factor was found apart from pathological stage pN and increased frequency of such prescription in the Calvados department.
Frequency in the practice of RP varied in the four departments and was markedly higher in the Tarn. In this department, frequency of RP was three times that in patients of equivalent age, clinical tumour stage and PSA levels in the other departments, whatever the sector of activity. The urological density in private sector was greater in this department regarding the other three. However, there was an equal access to radiotherapy in each department, specially represented in the private health sector. Differences in schools of medical thought and treatment habits of prostate cancer may explain such variability in a country like France. Furthermore, there was no systematic multidisciplinary approach in the French urological institutions in 1995 to counselling before the choice of treatment. Also, 87% of the 175 RP were carried out in the private sector, which also treated 73% of the initial population of 798 patients with prostate cancer. Such geographical variations in 15, 16 In Great Britain, RP has been advocated for only a small minority of patients. 16 The geographic variation in the application of RP, like other treatment modalities, seemed largely dependent on the preference of the consulted urologist and on related morbidity variations. 17 However, the therapeutic bene®t of RP for early prostate cancer has not been de®nitively demonstrated although some decision models suggested that RP would be preferred to other modalities for younger patients with high grade tumours. 10, 18 Some data from the literature suggest that organ-con®ned prostate cancer may be treated curatively by RP. 19 Further investigation and new socioeconomic factors must be identi®ed in future studies to de®ne and understand the mechanisms and interactions among geographic and demographic factors in the selection of patients to RP. 8 These results are the ®rst epidemiologic and clinical data on a surgical treatment of prostate cancer in the general population and they will be useful to analyse the clinical and biological follow-up of these 175 patients. At present, a 5-year survival study will be performed by the same investigators to assess the ef®cacy of RP in this population.
Conclusion
Our objective overview of the standpoint regarding RP in France revealed geographic variations in practice of RP, indicating regional differences among urologists in management of prostate cancer in 1995. The probability of undergoing RP was three times higher in one department than in the other departments, and was 2.6 times as high in the private sector. RP is widely predominant in the private sector in France with more than 85% of cases. This study provides the ®rst reference data on practice of RP in the French general population and will be soon completed by a 5-year survival analysis regarding the clinical follow-up.
